Abstract
Nucleoli are the sites where synthesis of rRNA and ribosomal assembly take place. Along with these “traditional” roles, the nucleolus controls cellular physiology and homeostasis. The cellular and molecular alterations associated with impaired nucleolar activity (“nucleolar stress”) have just started to be systematically explored in the nervous system taking advantage of newly available animal models lacking rRNA synthesis in specific neurons. These studies showed that nucleolar function is necessary for neuronal survival and that its modality of action differs between and within cell types. Nucleolar function is also crucial in pathology as it controls mitochondrial activity and critical stress signaling pathways mimicking hallmarks of human neurodegenerative diseases. This mini-review will focus on the modes of action of nucleolar stress and discuss how the manipulation of nucleolar activity might underscore novel strategies to extend neuronal function and survival.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Non-traditional roles of the nucleolus under physiological conditions
Nucleoli are non-membrane-bound structures within the nucleus where ribosomal RNA (rRNA) genes are transcribed. These atypical cellular organelles consist of three major compartments with specific functions: (1) fibrillar centers (FC, pre-rRNA synthesis), (2) dense fibrillar components (DFC, pre-RNA processing), and (3) granular components (GC, ribosome assembly). Their organization allows hosting a number of proteins and RNAs with an important role in various cellular processes. Thus the perturbation of nucleolar dynamic assembly exerts profound effects on several cellular functions [1]. A detailed description of nucleolar morphology and organization has been provided elsewhere [1, 2]. Here we focus on the mechanisms by which nucleolar activity may regulate neuronal function and survival and contribute especially to neurodegenerative diseases.
One intriguing mechanism to control embryonic development, differentiation, and survival is the nucleolar shuttling of cell cycle regulators and transcription factors dictating cell lineage to the nucleoplasm [1]. Moreover, rRNA repression seems required for the execution of differentiation programs. For example, during the embryonic development, transcription of rRNA genes is repressed by lineage-commitment transcription factors turning off the pluripotency genes [3]. During neural lineage commitment there is no direct evidence that rRNA transcription is inhibited; it is likely, however, that mechanisms involving nucleolar dynamics could be in play. For example in brain and retina the levels of the nucleolar protein nucleostemin, a controller of pre-rRNA processing, are rapidly reduced before cell cycle exit and neural differentiation [4, 5], suggesting that rRNA biosynthesis may have a regulatory effect on neurogenesis.
However, the major regulatory function associated with altered dynamics of nucleolar proteins is connected to the stress response and involves among others the release of ribosomal proteins (RPs) to the nucleoplasm. In response to adverse growth conditions, metabolic deficits, and oxidative stress, rRNA synthesis is downregulated by mechanisms involving transcription factors and epigenetic modifications [6]. This perturbation of nucleolar activity and integrity has been defined “nucleolar stress” [7]. Disruption of ribosome biogenesis releases RPs such as L5, L11, L23, and S7 into the nucleoplasm where they interfere with the activity of the E3 ubiquitin ligase Mdm2. Normally, this enzyme promotes proteasomal degradation of the transcription factor p53, but this function is impaired by RPs leading to accumulation of p53, which in turn initiates transcriptional and non-transcriptional programs [8]. By sensing cellular stress signals and transmitting them to the p53 stabilization system the nucleolus plays a fundamental role as a “stress sensor” [9]. Nucleolar stress may affect p53 levels also by non-RPs. The nucleolar protein nucleophosmin is dowregulated upon excitotoxic stimuli in neurons and alters p53 levels. Nevertheless, nucleophosmin-induced cell death appears to be p53 independent [10], suggesting that other yet unknown pathways control the stress response.
More regulatory functions can be postulated based on the observation that the nucleoli are also composed of RNAs, which are involved in the processing and maturation of cellular RNAs. For example, small nuclear RNAs are modified in the nucleolus, suggesting a possible link between nucleolar activity and splicing regulation [11]. In mature neurons changes in protein synthesis during synaptic activity are linked to increased number of nucleoli, by the postsynaptic protein AIDA-1d that regulates the generation of functional nucleoli by enhancing the release of small nuclear ribonucleoproteins (snRNPs) to the nucleoli [12].
More recently, a significant number of small non-coding RNAs (ncRNAs) regulating mRNA translation have been located in the GC of the nucleolus [13]. Although the role of this nucleolar transit is not understood, it is tempting to speculate that the regulation of microRNAs (miRNAs) processing and location is an additional mechanism linking nucleolar activity to protein synthesis regulation. Recently, it has been demonstrated that also specific stress stimuli such as acidosis and heat shock [14] induce immobilization of proteins by long ncRNAs in the nucleolus. In turn, reduced levels of ribosomal proteins may alleviate miRNA-mediated repression of translation initiation [15], highlighting the finely tuned cross-talk of the translational components that have their epicenter in the nucleolus. These premises and the increasing evidence of the role of ncRNAs in neuronal development and plasticity [16] support the unexplored functional link between nucleolus and ncRNAs in neuronal survival and activity.
In summary, by sequestering regulatory proteins and RNAs, and by influencing their dynamics upon specific stimuli, the nucleolus can finely tune distinct cellular functions beyond protein synthesis under physiological conditions.
Disruption of nucleolar activity in neurodegenerative diseases
It is well known that nucleolar malfunction contributes to the pathology of several rare human genetic disorders, such as Werner syndrome, dyskeratosis congenita, Treacher Collins syndrome and predisposes to certain forms of cancer [17, 18]. Moreover, decline in rRNA synthesis and nucleolar size occur during aging, which is the principal risk factor for neurodegenerative diseases [19, 20]. One of the major problems in neurodegenerative diseases is that the majority of cases are sporadic and, even when an inherited basis is ascertained, there is a high inter-individual variability. Thus, major efforts are directed to identify factors influencing disease onset and progression. Current treatments only help to ameliorate the symptoms but treatments that stop or reverse the pathology are still missing.
The interest on nucleolar stress is gaining momentum and the number of studies is rapidly growing over the last years [21] (Fig. 1). A focus on the role of nucleolar stress for neuronal activity and survival offers a basic and yet transformative perspective to the field of research on neurodegeneration. For example, silencing of rDNA may occur during early stages of Alzheimer´s disease (AD) pathology and play a role in AD-related ribosomal deficits and, ultimately, in dementia [22]. In line with this speculation, differential methylation activity of the human rDNA has been proposed as a mechanism to decrease rRNA gene expression in AD patients. Thus, rDNA specific methylation pattern could be used as a marker of the disease or of its progression [22].
Nucleolar integrity is disrupted in dopaminergic neurons of Parkinson´s disease (PD) patients in human post-mortem brain samples [23]. Treatment of mice with the neurotoxin MPTP (widely used in pharmacological models of PD to inhibit complex I activity in dopaminergic neurons), decreases rRNA synthesis causing early nucleolar disruption [23]. The findings demonstrating that impaired mitochondrial activity affects nucleolar function support the concept that nucleolar stress may occur at early disease stages and that contributes to the pathogenesis. Although the molecular basis of this control is still not understood, regulators of rRNA transcription might be involved. In fact, previous studies identified nucleolin as a protein-regulating rRNA synthesis and ribosome biogenesis [24, 25] and interacting with alpha-synuclein and DJ-1, two major proteins involved in familial PD pathogenesis. Strikingly, the expression levels of nucleolin are dramatically reduced in the substantia nigra pars compacta of human PD patients [26].
More recently, misfolded DJ-1 protein caused by L166P mutation has been shown to alter rRNA biogenesis in cellular models of PD [27], further supporting the association of impaired nucleolar activity with PD pathogenesis.
Nucleolar activity and structure are altered also in trinucleotide repeat disorders. These neurodegenerative diseases are associated with expansion of trinucleotide in repeats transcribed or untranscribed region of different genes. Huntington’s disease (HD), for instances, is associated with an expansion in exon 1 of the huntingtin gene, which leads to an aberrant polyglutamine tract in the huntingtin protein. Several studies have shown that transcription of rRNA genes is altered in HD. Rrs1 (regulator of ribosome synthesis), a protein inhibiting transcription of both rRNA and ribosomal protein genes, is highly expressed in a presymptomatic HD mouse model [28]. The levels of the basal RNA polymerase I factor UBF1 are decreased in cellular and animal HD models [29]. In post-mortem specimens of human HD cases, insoluble aggregates of huntingtin—a hallmark of this disorder—are found in the nucleolus [30]. The presence of insoluble protein aggregates is not limited to HD and is a rather common feature of neurodegenerative diseases. For instances, aggregates are found in the nucleolus of spinocerebellar ataxia patients, an inherited disorder caused by CAG or CTG expansion [30, 31]. In these neurodegenerative diseases nucleolin appears to play a role because CAG RNAs deprive rRNA promoter of this histone chaperone, downregulating rRNA transcription [32]. Abnormal interaction with nucleolin also accounts for the neurological disorder ataxia with oculomotor apraxia type 1, due to mutated aprataxin [33]. In several human cancers the angiogenic ribonuclease angiogenin (ANG) is upregulated and acts as a transcription factor, binding to rRNA promoters and stimulating rRNA transcription. A deficiency in ANG instead causes amyotrophic lateral sclerosis and degeneration of motor neurons [34]. Moreover, nucleolar activity may be repressed by inhibition of the proteasomal machinery, another hallmark of neurodegenerative diseases. RNA protein aggregates form within the nucleolus and are dependent on nucleolar integrity [35].
Dysfunction of snRNP biogenesis involves protein relocalization to the nucleolus in type I spinal muscular atrophy, an autosomal recessive disorder leading to degeneration and death of motor neurons caused by loss or mutations of the survival motor neuron 1 gene [36].
Mutant RNA molecules downregulating rRNA transcription in polyglutamine diseases [32] and mutant proteins altering the localization of nucleolar proteins in PD [27] show an active role of mutant gene products to cause rRNA transcription failure, supporting similar mechanistic studies in other neurodegenerative disorders. The association of nucleolar stress with neurodegenerative diseases raises the question of what cellular and molecular alterations depend on it.
A lesson from mouse models with nucleolar stress in specific populations of neurons: similarities with neuropathological conditions
Recently developed mouse models in which nucleolar function is specifically impaired have provided the first mechanistic insights into nucleolar stress in the nervous system. These models are based on the genetic ablation of TIF-IA, an evolutionary conserved transcription factor essential for the recruitment of RNA polymerase I to rRNA promoters. Since its identification, it was evident that TIF-IA activity is strongly dependent on external signals [37]. By now, it is known that TIF-IA is regulated by a variety of protein kinases at distinct serine residues: ERK and RSK in response to mitogenic signals [38], S6K in response to growth stimuli [39, 40], JNK2 in response to oxidative stress [41], AMPK in response to cellular energy status [42], PERK-dependent phosphorylation in response to endoplasmic reticulum stress [43] (Fig. 2). In addition, proteasome activity is required for pre-rRNA synthesis and TIF-IA may represent a potential link by which proteasomes are recruited to rRNA genes [44].
TIF-IA global knock-out in mice results in early embryonic lethality [45]. Specific loss of TIF-IA in neural progenitors leads to rRNA synthesis inhibition, nucleolar disruption, rapid apoptotic death of developing neurons, and consequent anencephalia [46]. The conditional ablation of TIF-IA in mice offers the major advantage of allowing focused investigation on the impact of nucleolar stress not only on cell cycle and growth regulation of neural progenitors, but also on quiescent postmitotic neurons in living organisms. Inactivation of the TIF-IA gene in adult dopaminergic neurons by a drug-inducible approach leads to a phenotype closely resembling PD, characterized by depletion of dopamine in the striatum, oxidative stress, mitochondrial impairment, progressive and differential loss of dopaminergic neurons in the substantia nigra pars compacta, as well as marked deficiencies in motor performance [23]. At the mechanistic level, mTOR activity is downregulated by TIF-IA ablation in dopaminergic neurons, underscoring a negative feedback that co-regulate and coordinate the translational process. In addition, the p53-dependent apoptosis in proliferating cells appears to be conserved in dopaminergic neurons under nucleolar stress, as shown by increased neuronal survival in absence of p53 [23].
The importance of p53 for the pathogenesis of neurodegenerative diseases has been clearly shown for HD, and further confirmed also for AD and PD. It is suggested that p53 could also serve as a convergence point in the molecular pathways for different neurodegenerative diseases [47]. p53 induces cell cycle arrest, senescence, and apoptosis in response to different stress signals such as DNA damage, hypoxia, nutrient deprivation, and nucleolar stress [8]. However, identifying the key elements that define a particular p53-mediated stress response outcome remains a central, yet unresolved, question. The identification of such downstream effectors is crucial to manipulate the deleterious consequences of cellular stress mediated by nucleolar disruption.
Future directions and perspectives
Nucleolar stress may start a progressive series of events affecting protein translation, which can be deregulated in consequence of altered distribution of nucleolar proteins and/or biogenesis of miRNAs, as well as of other cellular mechanisms. Because ribosomes seem to be “specialized” for the synthesis of specific mRNA [48], nucleolar stress by regulating ribosomal composition could specifically affect the translation of particular sets of mRNA in developing and adult neurons. The activation of p53 and the negative feedback on mTOR call in play metabolic and survival pathways executing cell fate decision, by inhibiting mitochondrial function and protein synthesis (Fig. 3).
The “TIF-IA-based models” will allow exploring initial adaptive mechanisms to stress conditions and by indirectly interfering with p53 turnover in specific cells can be used to gain understanding of context-dependent p53 functions. Some attempts have been reported to overexpress p53 in a constitutive and/or inducible way by the generation of transgenic mice [49], but engineered mice having high p53 activity in specific cell types are not available because of the difficulty to generate mutant mice which reproduce the natural levels of proteins. Ultimately, TIF-IA mutant mice can be used to develop and validate therapeutic intervention and identify biomarkers associated with a specific degenerative pattern (Table 1). Modulation of the Pol I transcriptional machinery is already proposed for anticancer therapies either by targeting specific components or the upstream pathways. Inhibition of Pol I in cancer cells has been shown to induce their apoptotic death [50]. Intriguingly, the TIF-IA mutant mice have been already useful for testing the neuroprotective role of the phosphatase PTEN in dopaminergic neurons, supporting their possible use for evaluating new therapeutic approaches [51].
Increasing evidence point to a multifactorial basis of neurodegenerative disease onset and progression. Perhaps there is time to bridge the gap between the reductionist approach focused on particular molecules involved in the pathology of a particular disease. The research for identifying common molecular checkpoints as possible new targets for pharmacotherapy seems necessary. Despite the total market of 2.2 billion USD estimated for anti-PD drugs major pharmaceutical companies discouraged by the relatively little progresses announced cuts to brain disorder research in favor of sequencing projects to identify genetic risk factors [52].
Investing more efforts in defining the toxic species causing rRNA transcription failure and the molecular alterations of nucleolar stress in specific cellular contexts will shed new light onto the mechanisms underlying differential vulnerability to stress conditions and indicate potential targets to manipulate them. Otherwise there will always be a missing piece in our understanding of neurological disorders and in our way to cure them.
References
Boisvert FM, van Koningsbruggen S, Navascues J, Lamond AI (2007) The multifunctional nucleolus. Nat Rev Mol Cell Biol 8:574–585
Boulon S, Westman BJ, Hutten S, Boisvert FM, Lamond AI (2010) The nucleolus under stress. Mol Cell 40:216–227
Ali SA, Dobson JR, Lian JB, Stein JL, van Wijnen AJ, Zaidi SK, Stein GS (2012) A Runx2-HDAC1 co-repressor complex regulates rRNA gene expression by modulating UBF acetylation. J Cell Sci 125:2732–2739
Paridaen JT, Janson E, Utami KH, Pereboom TC, Essers PB, van Rooijen C, Zivkovic D, MacInnes AW (2011) The nucleolar GTP-binding proteins Gnl2 and nucleostemin are required for retinal neurogenesis in developing zebrafish. Dev Biol 355:286–301
Lo D, Lu H (2010) Nucleostemin: another nucleolar "Twister" of the p53-MDM2 loop. Cell Cycle 9:3227–3232
Grummt I, Ladurner AG (2008) A metabolic throttle regulates the epigenetic state of rDNA. Cell 133:577–580
Pestov DG, Strezoska Z, Lau LF (2001) Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition. Mol Cell Biol 21:4246–4255
Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275–283
Olson MO (2004) Sensing cellular stress: another new function for the nucleolus? Sci STKE 2004:pe10
Marquez-Lona EM, Tan Z, Schreiber SS (2012) Nucleolar stress characterized by downregulation of nucleophosmin: a novel cause of neuronal degeneration. Biochem Biophys Res Commun 417:514–520
Gerbi SA, Borovjagin AV, Lange TS (2003) The nucleolus: a site of ribonucleoprotein maturation. Curr Opin Cell Biol 15:318–325
Jordan BA, Fernholz BD, Khatri L, Ziff EB (2007) Activity-dependent AIDA-1 nuclear signaling regulates nucleolar numbers and protein synthesis in neurons. Nat Neurosci 10:427–435
Politz JC, Hogan EM, Pederson T (2009) MicroRNAs with a nucleolar location. RNA 15:1705–1715
Audas TE, Jacob MD, Lee S (2012) Immobilization of proteins in the nucleolus by ribosomal intergenic spacer noncoding RNA. Mol Cell 45:147–157
Janas MM, Wang E, Love T, Harris AS, Stevenson K, Semmelmann K, Shaffer JM, Chen PH, Doench JG, Yerramilli SV et al (2012) Reduced expression of ribosomal proteins relieves microRNA-mediated repression. Mol Cell 46:171–186
Bian S, Sun T (2011) Functions of noncoding RNAs in neural development and neurological diseases. Mol Neurobiol 44:359–373
Johnson FB, Marciniak RA, Guarente L (1998) Telomeres, the nucleolus and aging. Curr Opin Cell Biol 10:332–338
Montanaro L, Trere D, Derenzini M (2008) Nucleolus, ribosomes, and cancer. Am J Pathol 173:301–310
Garcia Moreno LM, Cimadevilla JM, Gonzalez Pardo H, Zahonero MC, Arias JL (1997) NOR activity in hippocampal areas during the postnatal development and ageing. Mech Ageing Dev 97:173–181
Mattson MP, Magnus T (2006) Ageing and neuronal vulnerability. Nat Rev Neurosci 7:278–294
Hetman M, Pietrzak M (2012) Emerging roles of the neuronal nucleolus. Trends Neurosci 35:305–314
Pietrzak M, Rempala G, Nelson PT, Zheng JJ, Hetman M (2011) Epigenetic silencing of nucleolar rRNA genes in Alzheimer's disease. PLoS One 6:e22585
Rieker C, Engblom D, Kreiner G, Domanskyi A, Schober A, Stotz S, Neumann M, Yuan X, Grummt I, Schutz G et al (2011) Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling. J Neurosci 31:453–460
Cong R, Das S, Ugrinova I, Kumar S, Mongelard F, Wong J, Bouvet P (2012) Interaction of nucleolin with ribosomal RNA genes and its role in RNA polymerase I transcription. Nucleic Acids Res 40:9441–9454
Abdelmohsen K, Gorospe M (2012) RNA-binding protein nucleolin in disease. RNA Biol 9:799–808
Caudle WM, Kitsou E, Li J, Bradner J, Zhang J (2009) A role for a novel protein, nucleolin, in Parkinson's disease. Neurosci Lett 459:11–15
Vilotti S, Codrich M, Dal Ferro M, Pinto M, Ferrer I, Collavin L, Gustincich S, Zucchelli S (2012) Parkinson's disease DJ-1 L166P alters rRNA biogenesis by exclusion of TTRAP from the nucleolus and sequestration into cytoplasmic aggregates via TRAF6. PLoS One 7:e35051
Carnemolla A, Fossale E, Agostoni E, Michelazzi S, Calligaris R, De Maso L, Del Sal G, MacDonald ME, Persichetti F (2009) Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J Biol Chem 284:18167–18173
Lee J, Hwang YJ, Boo JH, Han D, Kwon OK, Todorova K, Kowall NW, Kim Y, Ryu H (2011) Dysregulation of upstream binding factor-1 acetylation at K352 is linked to impaired ribosomal DNA transcription in Huntington's disease. Cell Death Differ 18:1726–1735
Latonen L (2011) Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress. Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer. Bioessays 33:386–395
Baltanas FC, Casafont I, Weruaga E, Alonso JR, Berciano MT, Lafarga M (2011) Nucleolar disruption and cajal body disassembly are nuclear hallmarks of DNA damage-induced neurodegeneration in purkinje cells. Brain Pathol 21:374–388
Tsoi H, Lau TC, Tsang SY, Lau KF, Chan HY (2012) CAG expansion induces nucleolar stress in polyglutamine diseases. Proc Natl Acad Sci U S A 109:13428–13433
Becherel OJ, Gueven N, Birrell GW, Schreiber V, Suraweera A, Jakob B, Taucher-Scholz G, Lavin MF (2006) Nucleolar localization of aprataxin is dependent on interaction with nucleolin and on active ribosomal DNA transcription. Hum Mol Genet 15:2239–2249
Li S, Hu GF (2010) Angiogenin-mediated rRNA transcription in cancer and neurodegeneration. Int J Biochem Mol Biol 1:26–35
Latonen L, Moore HM, Bai B, Jaamaa S, Laiho M (2011) Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability. Oncogene 30:790–805
Tapia O, Bengoechea R, Palanca A, Arteaga R, Val-Bernal JF, Tizzano EF, Berciano MT, Lafarga M (2012) Reorganization of Cajal bodies and nucleolar targeting of coilin in motor neurons of type I spinal muscular atrophy. Histochem Cell Biol 137:657–667
Bodem J, Dobreva G, Hoffmann-Rohrer U, Iben S, Zentgraf H, Delius H, Vingron M, Grummt I (2000) TIF-IA, the factor mediating growth-dependent control of ribosomal RNA synthesis, is the mammalian homolog of yeast Rrn3p. EMBO Rep 1:171–175
Zhao J, Yuan X, Frodin M, Grummt I (2003) ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. Mol Cell 11:405–413
Mayer C, Zhao J, Yuan X, Grummt I (2004) mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev 18:423–434
Grewal SS, Evans JR, Edgar BA (2007) Drosophila TIF-IA is required for ribosome synthesis and cell growth and is regulated by the TOR pathway. J Cell Biol 179:1105–1113
Mayer C, Bierhoff H, Grummt I (2005) The nucleolus as a stress sensor: JNK2 inactivates the transcription factor TIF-IA and down-regulates rRNA synthesis. Genes Dev 19:933–941
Hoppe S, Bierhoff H, Cado I, Weber A, Tiebe M, Grummt I, Voit R (2009) AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply. Proc Natl Acad Sci U S A 106:17781–17786
DuRose JB, Scheuner D, Kaufman RJ, Rothblum LI, Niwa M (2009) Phosphorylation of eukaryotic translation initiation factor 2alpha coordinates rRNA transcription and translation inhibition during endoplasmic reticulum stress. Mol Cell Biol 29:4295–4307
Fatyol K, Grummt I (2008) Proteasomal ATPases are associated with rDNA: the ubiquitin proteasome system plays a direct role in RNA polymerase I transcription. Biochim Biophys Acta 1779:850–859
Yuan X, Zhou Y, Casanova E, Chai M, Kiss E, Grone HJ, Schutz G, Grummt I (2005) Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol Cell 19:77–87
Parlato R, Kreiner G, Erdmann G, Rieker C, Stotz S, Savenkova E, Berger S, Grummt I, Schutz G (2008) Activation of an endogenous suicide response after perturbation of rRNA synthesis leads to neurodegeneration in mice. J Neurosci 28:12759–12764
Chang JR, Ghafouri M, Mukerjee R, Bagashev A, Chabrashvili T, Sawaya BE (2012) Role of p53 in neurodegenerative diseases. Neurodegener Dis 9:68–80
Xue S, Barna M (2012) Specialized ribosomes: a new frontier in gene regulation and organismal biology. Nat Rev Mol Cell Biol 13:355–369
Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW, Evan GI (2005) Temporal dissection of p53 function in vitro and in vivo. Nat Genet 37:718–726
Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Anderes K et al (2012) Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22:51–65
Domanskyi A, Geissler C, Vinnikov IA, Alter H, Schober A, Vogt MA, Gass P, Parlato R, Schutz G (2011) Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models. FASEB J 25:2898–2910
Abbott A (2011) Novartis to shut brain research facility. Nature 480:161–162
Acknowledgments
We would like to thank our colleagues and collaborators for critical reading and editing of the manuscript.
This work was supported by the German Federal Ministry for Education and Research (BMBF) through NGFNplus grant FZK 01GS08142, the Helmholtz Gemeinschaft Deutscher Forschungszentren (HGF) through Alliance HelMA (HA-215), the DKFZ Intramural Funding Program, Polish National Science Center grant 2011/03/B/NZ7/05949 and the statutory funds of the Institute of Pharmacology, Polish Academy of Sciences.
Conflict of interest
The authors declare no conflict of interest.
Open Access
This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Parlato, R., Kreiner, G. Nucleolar activity in neurodegenerative diseases: a missing piece of the puzzle?. J Mol Med 91, 541–547 (2013). https://doi.org/10.1007/s00109-012-0981-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-012-0981-1